While therapies targeting EGFR and human epidermal growth factor 2 (HER2) receptors are currently being used in the treatment of HNSCC (reviewed in [138]), clinical therapies specifically targeting SphK1 in HNSCC are scarce. This evidence concerns the gene SPHK1 and head and neck squamous cell carcinoma.